ArticlePharmacoEconomics - open2017

Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib.

Jörg Mahlich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.